Slava Stamova (Rieber, TUD)-- «Polyclonal tumor - specific activation of cytotoxic effector cells by bispecific antibody constructs» (2009) (dresden-ipp.de)
The drug, manufactured by Amgen, is the first of a novel class of agents known as bispecific T cell engagers (BiTE), which consist of essentially two monoclonal antibodies joined together. (cancerresearch.org)
But this new work ups the ante by designing so - called bispecific antibodies that both promise to reverse latency and then do the mop - up work. (sciencemag.org)